Skip to content
Pierre Country
    • Homepage
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Author: Larimar Therapeutics

Posted Date:

June 29, 2026
  • Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

    Larimar Therapeutics
    June 29, 2026
  • Larimar Therapeutics Announces Investor Event on the Nomlabofusp Program for Friedreich’s Ataxia

    Larimar Therapeutics
    June 26, 2026